In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Kalani M WijesingheDepartments of Biochemistry and Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0009-0002-8748-9410 Chai-Wan KimCenter for Human Nutrition and Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390-9046, USA.ORCID 0000-0001-5105-2829 Emily O SchadDepartments of Biochemistry and Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0009-0009-4484-3767 Shuo LiDepartments of Biochemistry and Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0009-0009-7083-5154 Summer ChenDepartments of Biochemistry and Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0009-0009-1533-0057 Erin TakeshimaDepartments of Biochemistry and Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0009-0007-9421-2598 Chandni B KhandwalaDepartments of Biochemistry and Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-7784-6093 Desiree TilloCenter for Cancer Research Genomics Core, National Cancer Institute, National Institutes of Health, NIH, Building 41, RM D701, Bethesda, MD 20892, USA.ORCID 0000-0003-3568-6148 Andres M LebensohnLaboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, NIH, Building 37, RM 2056C, Bethesda, MD 20892, USA.ORCID 0000-0002-4224-8819 James A OlzmannDepartment of Molecular and Cell Biology, University of California at Berkeley, Berkeley, CA, USA and Department of Nutritional Sciences and Toxicology, University of California at Berkeley, Berkeley, CA 94720, USA.ORCID 0000-0001-7751-8316 Rajat RohatgiDepartments of Biochemistry and Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0001-7609-8858 Maia KinnebrewDepartments of Biochemistry and Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-7344-8231 Funding
Tissue Culture & Antibody Production CoreP01HL160487 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI Helen Haskell Hobbs · 2022 to 2026
$14.9MNew regulatory mechanisms of WNT signaling in development, stem cells and cancerZIABC011901 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LEBENSOHN, ANDRES · 2019 to 2025
$8.4MSupplement application for an Olympus automated microscopeR35GM118082 · NIGMS · STANFORD UNIVERSITY · PI RAJAT ROHATGI · 2016 to 2026
$7.6MUT Southwestern NORCP30DK127984 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI Jeffrey M Zigman · 2022 to 2026
$7.4MLipid droplet regulation and proteome dynamicsR01DK128099 · NIDDK · UNIVERSITY OF CALIFORNIA BERKELEY · PI OLZMANN, JAMES A · 2021 to 2025
$1.6MIntramural NIH HHS ZIA BC011901NHLBI NIH HHS P01 HL160487NIDDK NIH HHS P30 DK127984NIDDK NIH HHS R01 DK128099NIGMS NIH HHS R35 GM118082
6 · The paper itselfAbstract
Proper maintenance of plasma membrane (PM) cholesterol is essential for diverse processes ranging from animal development to pathogen evasion. Despite decades of study, the mechanisms governing cellular cholesterol regulation are incomplete. Using genome-wide screens we find that ACC1, the rate-limiting enzyme in fatty acid biosynthesis, regulates PM cholesterol transport. ACC1 loss causes a ~10-fold increase in PM accessible cholesterol in cells and mice. Mechanistically, we find that ACC1 regulates lipid droplet (LD) catabolism, and LDs are intimately tied to PM accessible cholesterol levels since reductions or elevations in their numbers block or promote cholesterol trafficking, respectively. Furthermore, LDs are required for cholesterol trafficking induced by 25-hydroxycholesterol, a modulator of inflammation and an interferon-stimulated second messenger that protects cells from pathogen invasion. This work identifies an unrecognized role for ACC1 and LDs in cholesterol regulation, which has implications for diseases where LD numbers are altered, from metabolic syndromes to neurodegeneration.
Indexed as
25-hydroxycholesterolACAT1 and ACAT2ACC1accessible cholesterolAMPKATGLCholesterolcholesterol esterslipid dropletmembrane traffickingplasma membraneSREBP2triacylglycerol
Identifiers
PMID40909529
PMCPMC12407704
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390